PMN — ProMIS Neurosciences Balance Sheet
0.000.00%
Last trade - 00:00- $112.10m
- $105.95m
Annual balance sheet for ProMIS Neurosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | Interim Report | ARS | ARS | ARS | ARS |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 17 | 5.91 | 12.6 | 13.3 | 6.15 |
| Net Total Accounts Receivable | |||||
| Net Total Receivables | — | — | 0.079 | — | 0.037 |
| Prepaid Expenses | |||||
| Total Other Current Assets | |||||
| Total Current Assets | 17.7 | 6.9 | 13.6 | 18.9 | 9.18 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 0.005 | 0 | 0 | — | — |
| Net Intangible Assets | |||||
| Total Assets | 17.7 | 6.92 | 13.6 | 18.9 | 9.18 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Current Liabilities | 0.929 | 6.41 | 9.35 | 2.22 | 10.4 |
| Long Term Debt | |||||
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 12.1 | 8.27 | 9.87 | 2.42 | 10.4 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 5.66 | -1.35 | 3.75 | 16.5 | -1.26 |
| Total Liabilities & Shareholders' Equity | 17.7 | 6.92 | 13.6 | 18.9 | 9.18 |
| Total Common Shares Outstanding |